Supplementary Material for: Medical and Surgical Management of Hidradenitis Suppurativa: A Review of International Treatment Guidelines and Implementation in General Dermatology Practice

<b><i>Background:</i></b> Hidradenitis suppurativa (HS) is a chronic painful skin disease that severely impairs patients’ quality of life. While high-quality trials of HS therapies remain limited, medical knowledge of best treatment practices is rapidly evolving, leading to the recent publication of multiple international treatment guidelines for HS. <b><i>Summary:</i></b> This review compares international HS treatment guidelines, describes evidence for effectiveness of common and emerging HS therapies, and provides guidance for integrating evidence-based HS care into practice. Although over 50 medical and procedural treatments are mentioned across international HS guidelines, only adalimumab and infliximab have grade B/weak recommendation or higher across all major guidelines. This review describes the appropriate patient selection and effectiveness of the most commonly used medical and procedural treatments for HS. It also includes recommendations for counseling, dosing, and duration of medical therapies as well as procedure videos for the practicing dermatologist.

**背景**：化脓性汗腺炎（Hidradenitis suppurativa, HS）是一种慢性疼痛性皮肤病，会严重损害患者的生活质量。尽管HS治疗相关的高质量临床试验仍较为有限，但学界对最佳诊疗方案的认知正快速迭代更新，近期多部HS国际治疗指南相继发布。**摘要**：本综述对比了HS的国际治疗指南，阐述了常用及新兴HS治疗手段的有效性证据，并为将循证HS诊疗融入临床实践提供指导。尽管国际HS指南中提及了50余种药物及操作治疗手段，但阿达木单抗（adalimumab）与英夫利昔单抗（infliximab）是所有主流指南中均获得B级/弱推荐及以上评级的药物。本综述详细说明了HS最常用药物及操作治疗手段的适用患者筛选标准与临床疗效，同时为执业皮肤科医师提供了药物治疗的咨询要点、给药方案及疗程建议，并配套相关操作教学视频。